
LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer
“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.
Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















